Previous FIP Digital Events

Catch up with all FIP previous webinars and digital events.


Creating development goal indicators – bridging data and outcomes (Southeast Asian Region)

17 October 2022

Summary of “Creating development goal indicators – bridging data and outcomes” events

FIP member organisations of each region selected some of the FIP Development Goals which are the priorities of their region.   Southeast Asia region: DG 12 (Pharmacy intelligence), DG 15 (People-centred care), and DG 19 (Patient safety).

FIP Global Pharmaceutical Observatory (GPO) team members have designed and developed indicators to support tracking progress towards the development goals.​ This globally validated list of indicators across all DGs will monitor progress worldwide and support each country in the process of transformation of their workforce, education, practice, and pharmaceutical science. FIP is developing a framework for selecting indicators and a monitoring and evaluating DGs.  This will enable the design of global Atlas (data visualization) dashboards that will drive and inform improvement and monitor trends over time. 

The process for tracking the development goals is first is to select priority DGs by identifying general, broad areas where there are active, ongoing national policies or projects mapped to the FIP DGs. The next step is to select the right indicators. Indicators are useful to provide measurable progress towards DGs, identify areas that need attention and support continuous improvement. After that, a monitoring and evaluation framework can be developed. Lastly, continuous development can be provided by regularly updating Atlas dashboards to present how the data changes over time. Atlas dashboards can include an actionable overview of a limited set of key indicators with novel ways of bringing attention to those areas that are advancing the profession or experiencing challenges. These have significant potential to support regular reviews of DG progress and improve the data quality.

Southeast Asian Region Panel Discussion on DG priorities and data requirements:

  • The 21 DGs are aligned with the health system transformation in Indonesia, especially for DG 4 (Advanced and specialist development), DG 12 (Pharmacy intelligence and DG 20 (Digital health). DG 4 (Advanced and specialist development) is the most aligned DG in relation with transformation agenda on health human resources in Indonesia.
  •  In Sri Lanka, the priority goals are DG 1 (Academic capacity), DG 2 (Early career training strategy), DG 5 (Competency development), and DG 9 (Continuing professional development strategies). DG 1 is important because Sri Lanka has different pathways of creating pharmacists with most of the other countries, there are 3 programs with different qualification.
  • Sri Lanka needs is to collect the data of pharmacists working in different sectors, because all pharmacists are having the same certificate and this not mention the area of practice.
  • Currently, Sri Lanka does not have a well-organized education and training program to support early career pharmacists, or a development framework to support career development and no continuing professional development program for pharmacists.
  • All 21 DGs resonate with the needs in India. The priority areas are DG 12 (Pharmacy Intelligence), DG 15 (People-centred care) and DG 19 (Patient safety). Pharmacy council of India is maintaining the data about number of pharmacists and number of colleges which needs to be updated regularly and available to the policy makers as well as the people.
  • India is currently developing the data regarding available pharmacists and their area of work.
  • Indonesia needs the data of pharmacists that provide services across nation, their competencies profile and progress on the career. Indonesian Pharmacists Association already created the information system to provide the data on number of pharmacists, however, the data is still lacking the competencies profile and the progress on their career pathway for advanced practice perspective.